Tema GLP-1 Obesity & Cardiometabolic ETF (HRTS)
| Assets | $69.49M |
| Expense Ratio | 0.75% |
| PE Ratio | 34.02 |
| Shares Out | 2.36M |
| Dividend (ttm) | $0.47 |
| Dividend Yield | 1.58% |
| Ex-Dividend Date | Dec 11, 2024 |
| Payout Ratio | 53.83% |
| 1-Year Return | -1.29% |
| Volume | 8,936 |
| Open | 29.52 |
| Previous Close | 29.64 |
| Day's Range | 29.52 - 29.77 |
| 52-Week Low | 28.81 |
| 52-Week High | 36.03 |
| Beta | n/a |
| Holdings | 45 |
| Inception Date | Nov 20, 2023 |
About HRTS
Fund Home PageThe Tema GLP-1 Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.
Top 10 Holdings
44.42% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 7.52% |
| Vertex Pharmaceuticals Incorporated | VRTX | 5.19% |
| Alnylam Pharmaceuticals, Inc. | ALNY | 5.11% |
| BridgeBio Pharma, Inc. | BBIO | 4.41% |
| Crinetics Pharmaceuticals, Inc. | CRNX | 3.98% |
| Ascendis Pharma A/S | ASND | 3.91% |
| Chugai Pharmaceutical Co., Ltd. | 4519 | 3.88% |
| AstraZeneca PLC | AZN | 3.68% |
| Cytokinetics, Incorporated | CYTK | 3.41% |
| Novo Nordisk A/S | NOVO.B | 3.32% |
News
Disruptive Theme of the Week: 2024's Top Investment Themes & Trends
2024 was an amazing year for investment performance, with the broad market S&P 500 TR Index up over 28%. There were also some serious ETF milestones achieved this year.
Disruptive Theme of the Week – Breakthroughs in Medicine
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakth...
Disruptive Theme of the Week: Happy Post-Election Themes
With the completion of a close presidential election, roughly half of us are likely disappointed regardless of the winner. To counter the post-election blues, I identified some “happy” ETF themes to c...
How to capitalize on the weight loss revolution with Tema Obesity & Cardiometabolic ETF (HRTS)
The weight loss revolution sparked by Novo Nordisk last year is attracting many investors towards the high risk biotech sector. An ETF like HRTS gives a lower risk exposure to the sector.
HRTS: Generating Alpha In Obesity Treatment
The Tema Obesity & Cardiometabolic ETF is a new actively managed fund focusing on the obesity treatment market. The investment strategy includes a mix of cash flow-positive companies, high-growth comp...
HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside
By 2030, the weight loss drug market is estimated to reach a significant size, attracting many competitors due to the high prevalence of obesity-related comorbidities. The Tema Obesity & Cardiometabol...
Looking at Next Gen of Weight Loss: Tema ETFs CEO
Tema Obesity & Cardiometabolic ETF (HRTS) currently holds 46 companies focused on GLP-1, obesity, and weight-loss. Tema ETFs CEO and Founder Maurits Pot says we're trying to build a product that goes ...
What's Next for Weight Loss Stocks?
Tema Obesity & Cardiometabolic ETF is up 4% year-to-date. David Song discusses health care and ETF investing.
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Sign of top or next pop? Rush of new offerings spring up around Mag 7, weight loss
Sign of top or next pop? Rush of new offerings spring up around Mag 7, weight loss.
Tema ETFs hops on weight-loss drug frenzy with its new cardiovascular fund
Tema ETFs has launched a new exchange traded fund (ETF) that tracks popular drugmakers like Novo Nordisk and Eli Lilly , aiming to tap into growing demand for their weight-loss and diabetes drugs.